First, oxaliplatin has been reported to induce immunogenic cell death and increase tumor-specific effector T cell infiltration (29), hence the combination of anti-PD-1 antibody with oxaliplatin-based chemotherapies might induce an additive antitumor effect, which actually has been demonstrated in ATTRACTION-4 (34) and ORIENT-16 (35) studies, whereas, pembrolizumab plus cisplatin-based chemotherapy didn’t show survival benefit (23). This evidence concerns the gene PDCD1 and neoplasm.